- In February 2021, Ponce Therapeutics, a biotechnology company based in the United States, unveiled its inaugural research and development initiative aimed at addressing skin conditions like Bowen's disease and aging. The company has recruited its initial team of scientists to spearhead this endeavor. The primary focus of this research and development effort will be on the p16 cell proliferation inhibitor, which is notably prevalent in Bowen's disease. This strategic plan is expected to pave the way for the company's debut product, slated for regulatory approval and subsequent market launch
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment (Electrosurgery, Cryosurgery, Lazer Surgery, 5-Aminolevulinic Acid-mediated Photodynamic Therapy, and Medication), Drug Type (5-Fluorouracil, Imiquimod, Podophyllin, and Cidofovir), Dosage (Injection, Solution, and Cream), Route of Administration (Topical, Intravenous, and Other), End-Users (Clinic, Hospital and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Bowenoid Papulosis Treatment Market size was valued at USD 497.86 USD Million in 2023.
The Global Bowenoid Papulosis Treatment Market is projected to grow at a CAGR of 6.34% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
